Sign in or create an account to add this stock to your watchlist.
About SAGE Therapeutics (NASDAQ:SAGE)
Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which has completed Phase II clinical trials for the treatment of PPD, major depressive disorders, bipolar depression, Parkinson's disease, and sleep disorders; and SAGE-718, an oxysterol-based positive allosteric modulator of NMDA receptors for the treatment of depression, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, Huntington's disease, and neuropathic pain. In addition, its product pipeline comprises SAGE-324, a novel neuroactive steroid for the treatment of GABA hypofunction; and product pipeline that are in preclinical stage includes SAGE-689 and SAGE-105 novel GABAA receptor modulators The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SAGE
CUSIPN/A
Phone617-299-8380
Debt
Debt-to-Equity RatioN/A
Current Ratio28.92
Quick Ratio28.92
Price-To-Earnings
Trailing P/E Ratio-22.31
Forward P/E Ratio-18.76
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$22.77 per share
Price / Book6.95
Profitability
EPS (Most Recent Fiscal Year)($7.09)
Net Income$-270,120,000.00
Net MarginsN/A
Return on Equity-57.73%
Return on Assets-52.95%
Miscellaneous
Employees257
Outstanding Shares46,520,000
SAGE Therapeutics (NASDAQ:SAGE) Frequently Asked Questions
What is SAGE Therapeutics' stock symbol?
SAGE Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."
How were SAGE Therapeutics' earnings last quarter?
SAGE Therapeutics Inc (NASDAQ:SAGE) announced its quarterly earnings data on Thursday, May, 3rd. The biopharmaceutical company reported ($1.68) EPS for the quarter, beating the Zacks' consensus estimate of ($1.84) by $0.16. During the same quarter in the previous year, the company earned ($1.52) EPS. View SAGE Therapeutics' Earnings History.
What price target have analysts set for SAGE?
15 brokerages have issued 1-year price targets for SAGE Therapeutics' shares. Their forecasts range from $86.00 to $280.00. On average, they expect SAGE Therapeutics' share price to reach $185.20 in the next twelve months. View Analyst Ratings for SAGE Therapeutics.
What are Wall Street analysts saying about SAGE Therapeutics stock?
Here are some recent quotes from research analysts about SAGE Therapeutics stock:
- 1. Canaccord Genuity analysts commented, "We like the setup heading into a catalyst-rich 2H18/2019E We are updating our model after SAGE reported its 1Q18 and provided a corporate update today (5/3). With its first product, brexanolone IV for postpartum depression (PPD), filed with potential commercialization in 1H19, and a robust pipeline of neuro- focused assets led by SAGE-217, our BUY thesis on the stock remains unchanged. In short, we like SAGE’s pipeline that targets several large central nervous system (CNS) indications where the unmet need is high (e.g., major depressive disorder, PPD, Parkinson’s, etc.) and the scarcity value that comes with robust/ripening CNS platforms. With the stock having pulled back ~25% since its 52-week high on 1/31/18, we like the setup heading into a catalyst-rich 2H18/2019E. Our DCF-based price target remains unchanged at $210." (5/3/2018)
- 2. Cowen Inc analysts commented, "We note that neither Mylan nor Biocon would comment on Neulasta’s updated timing. We spoke with a manufacturing consultant who believed that biosimilar Neulasta would not receive an approval until the Form 483 issues were resolved. We expect an update on Mylan’s earnings call on Wednesday, 5/9/18. Biocon Form 483: Biocon announced yesterday (5/1/18) that the FDA issued a Form 483 with 7 observations relating to the company’s Bangalore, India site. As a reminder, MYL has a partnership with Biocon to produce biosimilars Neulasta/Herceptin out of the same facility. The TAD for biosimilar Neulasta is on 6/4/18. Biocon noted that the observations were largely procedural and aimed at continuous improvement. Further, the company indicated that it would respond to the FDA well within" the typical 15 day response period." (5/3/2018)
- 3. Needham & Company LLC analysts commented, "FY 2017 results were generally in line with expectations. We note that ‘217 Phase 2 PPD data are now expected in 4Q18 (was 2Q). The additional delay (previously moved from 1Q18 to 2Q18) is reportedly due to an increase in target enrollment (now ~140 PPD patients). We still anticipate a positive outcome and think running a full-scale trial makes sense given prior supportive data. With the robust size and design of the study, we believe it could serve as a registration trial and help streamline ‘217 time to market. Sage still plans to conduct several additional well powered trials (insomnia, bipolar depression, PD tremor) with oral ‘217 this year. Further evaluation of ‘217 for MDD, including potential initiation of pivotal Phase 3 development is also anticipated in 2018 (unch). BUY." (2/23/2018)
Who are some of SAGE Therapeutics' key competitors?
Some companies that are related to SAGE Therapeutics include Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), Teva Pharmaceutical Industries (TEVA), Mylan (MYL), BioMarin Pharmaceutical (BMRN), Grifols (GRFS), UCB (UCBJF), Ono Pharmaceutical (OPHLF), Nektar Therapeutics (NKTR), Merck Group (MKGAF), Genmab (GNMSF), Perrigo (PRGO), BeiGene (BGNE), Jazz Pharmaceuticals (JAZZ) and Alnylam Pharmaceuticals (ALNY).
Who are SAGE Therapeutics' key executives?
SAGE Therapeutics' management team includes the folowing people:
- Mr. Michael Cloonan, Chief Bus. Officer (Age 47)
- Dr. Jeffrey M. Jonas, CEO, Pres & Director (Age 65)
- Ms. Kimi E. Iguchi, CFO & Treasurer (Age 56)
- Dr. Heinrich Schlieker Ph.D., Sr. VP of Technical Operations
- Dr. Albert J. Robichaud, Chief Scientific Officer (Age 57)
Has SAGE Therapeutics been receiving favorable news coverage?
Headlines about SAGE stock have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. SAGE Therapeutics earned a coverage optimism score of 0.04 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 46.55 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are SAGE Therapeutics' major shareholders?
SAGE Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.11%), OppenheimerFunds Inc. (3.36%), BB Biotech AG (2.15%), Palo Alto Investors LP (1.76%), JPMorgan Chase & Co. (1.55%) and Eagle Asset Management Inc. (1.32%). Company insiders that own SAGE Therapeutics stock include Albert Robichaud, James M Frates, Jeffrey M Jonas, Kevin P Starr, Kimi Iguchi, Stephen Kanes and Steven M Paul. View Institutional Ownership Trends for SAGE Therapeutics.
Which major investors are selling SAGE Therapeutics stock?
SAGE stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Oak Ridge Investments LLC, JPMorgan Chase & Co., DekaBank Deutsche Girozentrale, BB Biotech AG, Element Capital Management LLC, Eventide Asset Management LLC and Franklin Resources Inc.. Company insiders that have sold SAGE Therapeutics company stock in the last year include Albert Robichaud, James M Frates, Jeffrey M Jonas, Kevin P Starr, Kimi Iguchi, Stephen Kanes and Steven M Paul. View Insider Buying and Selling for SAGE Therapeutics.
Which major investors are buying SAGE Therapeutics stock?
SAGE stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., American Century Companies Inc., Victory Capital Management Inc., Point72 Asset Management L.P., Bamco Inc. NY, Hood River Capital Management LLC, OppenheimerFunds Inc. and DAFNA Capital Management LLC. View Insider Buying and Selling for SAGE Therapeutics.
How do I buy shares of SAGE Therapeutics?
Shares of SAGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is SAGE Therapeutics' stock price today?
One share of SAGE stock can currently be purchased for approximately $158.17.
How big of a company is SAGE Therapeutics?
SAGE Therapeutics has a market capitalization of $7.65 billion. The biopharmaceutical company earns $-270,120,000.00 in net income (profit) each year or ($7.09) on an earnings per share basis. SAGE Therapeutics employs 257 workers across the globe.
How can I contact SAGE Therapeutics?
SAGE Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-299-8380 or via email at [email protected]
MarketBeat Community Rating for SAGE Therapeutics (SAGE)
MarketBeat's community ratings are surveys of what our community members think about SAGE Therapeutics and other stocks. Vote "Outperform" if you believe SAGE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SAGE will underperform the S&P 500 over the long term. You may vote once every thirty days.
SAGE Therapeutics (NASDAQ:SAGE) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
15 Wall Street analysts have issued ratings and price targets for SAGE Therapeutics in the last 12 months. Their average twelve-month price target is $185.20, suggesting that the stock has a possible upside of 17.09%. The high price target for SAGE is $280.00 and the low price target for SAGE is $86.00. There are currently 1 sell rating, 1 hold rating and 13 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.80 | 2.80 | 2.79 | 3.00 |
| Ratings Breakdown: | 1 Sell Rating(s)
1 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
1 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
1 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
13 Buy Rating(s)
1 Strong Buy Rating(s) |
| Consensus Price Target: | $185.20 | $185.20 | $171.2143 | $105.7143 |
| Price Target Upside: | 17.09% upside | 18.54% upside | 10.18% upside | 23.40% upside |
SAGE Therapeutics (NASDAQ:SAGE) Consensus Price Target History
SAGE Therapeutics (NASDAQ:SAGE) Analyst Ratings History
Show:
(Data available from 5/25/2016 forward)
SAGE Therapeutics (NASDAQ:SAGE) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
SAGE Therapeutics (NASDAQ SAGE) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 6.10%
SAGE Therapeutics (NASDAQ SAGE) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/8/2018 | James M Frates | Director | Sell | 7,000 | $154.00 | $1,078,000.00 | 12,000 |  |
| 4/25/2018 | Kimi Iguchi | CFO | Sell | 28,153 | $142.73 | $4,018,277.69 | 63,499 | |
| 4/23/2018 | Kimi Iguchi | CFO | Sell | 12,135 | $144.48 | $1,753,264.80 | 63,499 | |
| 4/18/2018 | Kevin P Starr | Director | Sell | 59,000 | $168.85 | $9,962,150.00 | 326,817 | |
| 3/6/2018 | Steven M Paul | Director | Sell | 58,139 | $172.00 | $9,999,908.00 | 632,712 | |
| 1/10/2018 | Stephen Kanes | Insider | Sell | 44,000 | $177.18 | $7,795,920.00 | 46,348 | |
| 12/21/2017 | Jeffrey M Jonas | CEO | Sell | 210,247 | $157.45 | $33,103,390.15 | 211,473 | |
| 12/14/2017 | Albert Robichaud | Insider | Sell | 60,000 | $159.43 | $9,565,800.00 | 152,759 | |
| 1/13/2017 | Kimi Iguchi | CFO | Sell | 10,000 | $53.92 | $539,200.00 | | |
| 11/17/2016 | Kimi Iguchi | CFO | Sell | 4,000 | $51.77 | $207,080.00 | 75,739 | |
| 11/11/2016 | Kimi Iguchi | CFO | Sell | 1,500 | $50.59 | $75,885.00 | 79,739 | |
| 9/7/2016 | Kimi Iguchi | CFO | Sell | 2,500 | $40.93 | $102,325.00 | 81,239 | |
| 7/12/2016 | Albert Robichaud | Insider | Sell | 22,000 | $40.00 | $880,000.00 | 140,222 | |
| 7/12/2016 | Kimi Iguchi | CFO | Sell | 5,000 | $49.55 | $247,750.00 | 83,739 | |
| 5/16/2016 | Kevin P Starr | Director | Sell | 850,000 | $31.25 | $26,562,500.00 | 65,227 | |
| 4/19/2016 | Stephen Kanes | Insider | Sell | 21,000 | $38.00 | $798,000.00 | 25,948 | |
| 1/25/2016 | Albert Robichaud | Insider | Sell | 20,000 | $40.02 | $800,400.00 | 162,222 | |
| 9/28/2015 | Stephen Kanes | insider | Sell | 6,000 | $46.42 | $278,520.00 | 46,948 | |
| 9/8/2015 | Kimi Iguchi | CFO | Sell | 3,000 | $54.84 | $164,520.00 | 84,563 | |
| 9/1/2015 | Steven M. Paul | Director | Sell | 20,000 | $52.41 | $1,048,200.00 | 683,650 | |
| 8/31/2015 | Stephen Kanes | Insider | Sell | 12,000 | $53.12 | $637,440.00 | 31,948 | |
| 7/23/2015 | Jeffrey M Jonas | Insider | Sell | 3,000 | $76.79 | $230,370.00 | | |
| 7/6/2015 | Kimi Iguchi | CFO | Sell | 4,000 | $68.00 | $272,000.00 | | |
| 7/1/2015 | Albert Robichaud | Insider | Sell | 16,000 | $72.13 | $1,154,080.00 | | |
| 7/1/2015 | Steven M Paul | Director | Sell | 20,000 | $69.40 | $1,388,000.00 | | |
| 6/24/2015 | Stephen Kanes | Insider | Sell | 6,000 | $74.06 | $444,360.00 | | |
| 6/16/2015 | Jeffrey M Jonas | Insider | Sell | 198,600 | $77.36 | $15,363,696.00 | | |
| 6/8/2015 | Thomas Anderson | Insider | Sell | 5,500 | $79.65 | $438,075.00 | | |
| 6/1/2015 | Albert Robichaud | Insider | Sell | 16,000 | $72.80 | $1,164,800.00 | | |
| 6/1/2015 | Steven M Paul | Director | Sell | 20,000 | $72.34 | $1,446,800.00 | | |
| 2/25/2015 | Stephen Kanes | Insider | Sell | 6,000 | $42.05 | $252,300.00 | | |
| 1/26/2015 | Stephen Kanes | Insider | Sell | 6,000 | $37.29 | $223,740.00 | | |
| 7/23/2014 | James M Frates | Director | Buy | 5,000 | $18.00 | $90,000.00 | | |
| 7/23/2014 | Stephen Kanes | Insider | Buy | 3,000 | $18.00 | $54,000.00 | | |
(Data available from 1/1/2013 forward)
SAGE Therapeutics (NASDAQ SAGE) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Here's Why Marinus Pharmaceuticals Rose as Much as 18.4% Today
finance.yahoo.com - May 24 at 5:08 PM |
 | SAGE Therapeutics Inc (SAGE) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 24 at 3:28 AM |
| Sage Therapeutics to Present at Bernstein’s 34th Annual Strategic Decisions Conference
finance.yahoo.com - May 23 at 8:42 AM |
| Albireo (ALBO) & SAGE Therapeutics (SAGE) Financial Comparison
www.americanbankingnews.com - May 21 at 3:17 PM |
| Zacks: Brokerages Anticipate SAGE Therapeutics Inc (SAGE) Will Post Earnings of -$1.93 Per Share
www.americanbankingnews.com - May 19 at 3:22 AM |
| SAGE Therapeutics (SAGE) Lifted to Hold at BidaskClub
www.americanbankingnews.com - May 15 at 12:36 AM |
| Insider Selling: SAGE Therapeutics Inc (SAGE) Director Sells 7,000 Shares of Stock
www.americanbankingnews.com - May 8 at 7:39 PM |
| Sage Therapeutics to Present at Bank of America Merrill Lynch 2018 Health Care Conference
finance.yahoo.com - May 8 at 8:49 AM |
| Edited Transcript of SAGE earnings conference call or presentation 3-May-18 12:00pm GMT
finance.yahoo.com - May 4 at 8:48 AM |
| SAGE Therapeutics' (SAGE) "Buy" Rating Reaffirmed at Cowen
www.americanbankingnews.com - May 4 at 12:01 AM |
| SAGE Therapeutics (SAGE) Given a $210.00 Price Target at Canaccord Genuity
www.americanbankingnews.com - May 3 at 10:55 PM |
 | Lucky Seven: An Introduction To My Top Biotechnology Picks
seekingalpha.com - May 3 at 4:57 PM |
 | Sage Therapeutics Announces First Quarter 2018 Financial Results and Provides Update on Pipeline and Progress ...
www.businesswire.com - May 3 at 4:57 PM |
 | BRIEF-Sage Therapeutics Reports Quarterly Loss Per Share Of $1.68
www.reuters.com - May 3 at 4:57 PM |
| Sage Therapeutics 2018 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 3 at 4:57 PM |
| SAGE Therapeutics (SAGE) Issues Earnings Results, Beats Expectations By $0.16 EPS
www.americanbankingnews.com - May 3 at 2:54 PM |
| Sage Therapeutics Announces First Quarter 2018 Financial Results and Provides Update on Pipeline and Progress toward Launch Readiness
finance.yahoo.com - May 3 at 8:45 AM |
| SAGE Therapeutics (SAGE) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - May 2 at 8:15 PM |
| SAGE Therapeutics (SAGE) Upgraded to "Strong-Buy" at ValuEngine
www.americanbankingnews.com - May 2 at 6:30 PM |
| Brokerages Expect SAGE Therapeutics Inc (SAGE) Will Post Earnings of -$1.85 Per Share
www.americanbankingnews.com - May 1 at 1:23 PM |
| Ovid Therapeutics: Beaten-Down IPO With Upcoming 2018 Catalysts
seekingalpha.com - May 1 at 8:54 AM |
| SAGE Therapeutics Inc (SAGE) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 29 at 3:24 AM |
| CNBC's 2018 Stock Draft Round 3
finance.yahoo.com - April 27 at 9:12 AM |
| SAGE Therapeutics Inc (SAGE) CFO Kimi Iguchi Sells 12,135 Shares
www.americanbankingnews.com - April 25 at 7:10 PM |
| Kimi Iguchi Sells 28,153 Shares of SAGE Therapeutics Inc (SAGE) Stock
www.americanbankingnews.com - April 25 at 7:10 PM |
| Sage Therapeutics to Report First Quarter 2018 Financial Results on Thursday, May 3, 2018
finance.yahoo.com - April 24 at 8:47 AM |
| Sage files U.S. marketing application for PPD med brexanolone; shares up 1% premarket
seekingalpha.com - April 23 at 8:38 AM |
| Sage Therapeutics Submits New Drug Application to U.S. FDA for Intravenous Brexanolone in the Treatment of Postpartum Depression
finance.yahoo.com - April 23 at 8:38 AM |
| Sage Therapeutics asks FDA to approve lead drug for postpartum depression
finance.yahoo.com - April 23 at 8:38 AM |
| Sage Therapeutics down 7% on Biogen/Ionis deal
seekingalpha.com - April 20 at 4:57 PM |
| Why Stanley Black & Decker, ManpowerGroup, and Sage Therapeutics Slumped Today
finance.yahoo.com - April 20 at 4:57 PM |
| Kevin P. Starr Sells 59,000 Shares of SAGE Therapeutics Inc (SAGE) Stock
www.americanbankingnews.com - April 19 at 7:18 PM |
| Sage Therapeutics to Present Brexanolone Postpartum Depression Data and SAGE-217 Major Depressive Disorder Data at Upcoming Spring Medical Meetings
finance.yahoo.com - April 17 at 5:26 PM |
| SAGE Therapeutics (SAGE) Downgraded by BidaskClub
www.americanbankingnews.com - April 14 at 9:17 PM |
| Brokerages Anticipate SAGE Therapeutics Inc (SAGE) to Post -$1.85 EPS
www.americanbankingnews.com - April 14 at 3:11 PM |
| Sage takeover rumors unfounded
seekingalpha.com - April 10 at 5:03 PM |
 | Noteworthy Tuesday Option Activity: DDS, COST, SAGE
www.nasdaq.com - April 10 at 5:03 PM |
| SAGE Therapeutics (SAGE) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - April 5 at 12:30 AM |
| SAGE Therapeutics Inc (SAGE) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 4 at 3:22 AM |
| ValuEngine Upgrades SAGE Therapeutics (SAGE) to "Buy"
www.americanbankingnews.com - April 3 at 12:30 AM |
| SAGE Therapeutics Inc (SAGE) Expected to Post Earnings of -$1.85 Per Share
www.americanbankingnews.com - March 28 at 5:24 PM |
| Sage CEO on post-partum depression, innovation for the co...
finance.yahoo.com - March 28 at 4:55 PM |
| Sage Therapeutics CEO: Have to weigh investor returns but will price postpartum drug ‘fairly’
finance.yahoo.com - March 28 at 4:55 PM |
| Canaccord Genuity Analysts Give SAGE Therapeutics (SAGE) a $210.00 Price Target
www.americanbankingnews.com - March 26 at 8:37 AM |
| SAGE Therapeutics (SAGE) Earns "Buy" Rating from Cowen
www.americanbankingnews.com - March 20 at 9:22 PM |
| Corbus Pharmaceuticals (CRBP) vs. SAGE Therapeutics (SAGE) Head-To-Head Contrast
www.americanbankingnews.com - March 18 at 5:20 PM |
 | Pre-Market Technical Scan on Biotech Equities -- Riot Blockchain, Sage ...
www.prnewswire.com - March 16 at 8:58 AM |
 | Pre-Market Technical Scan on Biotech Equities -- Riot Blockchain, Sage Therapeutics, Sarepta Therapeutics, and Sierra Oncology
www.bizjournals.com - March 16 at 8:58 AM |
| See what the IHS Markit Score report has to say about SAGE Therapeutics Inc.
finance.yahoo.com - March 15 at 5:35 PM |
 | Analyst Has 4 Favorite Biotechnology Stocks to Buy Now
www.msn.com - March 15 at 5:35 PM |
SAGE Therapeutics (NASDAQ:SAGE) SEC Filings
This page is loading this company's SEC Filings. Please wait...
SAGE Therapeutics (NASDAQ:SAGE) Income Statement, Balance Sheet and Cash Flow Statement
SAGE Therapeutics (NASDAQ SAGE) Stock Chart for Friday, May, 25, 2018
Loading chart…
